MicroRNAs in neurodegenerative diseases and their therapeutic potential.

MicroRNAs (miRNAs) are abundant, endogenous, short, noncoding RNAs that act as important post-transcriptional regulators of gene expression by base-pairing with their target mRNA. During the last decade, substantial knowledge has accumulated regarding the biogenesis of miRNAs, their molecular mechanisms and functional roles in a variety of cellular contexts. Altered expression of certain miRNA molecules in the brains of patients with neurodegenerative diseases such as Alzheimer and Parkinson suggests that miRNAs could have a crucial regulatory role in these disorders. Polymorphisms in miRNA target sites may also constitute an important determinant of disease risk. Additionally, emerging evidence points to specific miRNAs targeting and regulating the expression of particular proteins that are key to disease pathogenesis. Considering that the amount of these proteins in susceptible neuronal populations appears to be critical to neurodegeneration, miRNA-mediated regulation represents a new target of significant therapeutic prospects. In this review, the implications of miRNAs in several neurodegenerative disorders and their potential as therapeutic interventions are discussed.

[1]  A. Roses,et al.  Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways , 2008 .

[2]  Oliver H. Tam,et al.  Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes , 2008, Nature.

[3]  V. Scaria,et al.  Antagomirzymes: oligonucleotide enzymes that specifically silence microRNA function. , 2009, Angewandte Chemie.

[4]  Harry T Orr,et al.  Trinucleotide repeat disorders. , 2007, Annual review of neuroscience.

[5]  N. Bonini,et al.  Short ArticleMicroRNA Pathways Modulate Polyglutamine-Induced Neurodegeneration , 2006 .

[6]  Thomas Tuschl,et al.  Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. , 2004, RNA.

[7]  Eden R Martin,et al.  Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. , 2004, American journal of human genetics.

[8]  H. Akiyama,et al.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. , 2006, Biochemical and biophysical research communications.

[9]  Danish Sayed,et al.  MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. , 2008, Molecular biology of the cell.

[10]  R J Fletterick,et al.  Structural clues to prion replication. , 1994, Science.

[11]  Gaofeng Wang,et al.  Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. , 2008, American journal of human genetics.

[12]  Sanghyuk Lee,et al.  MicroRNA genes are transcribed by RNA polymerase II , 2004, The EMBO journal.

[13]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[14]  V. Kim,et al.  The nuclear RNase III Drosha initiates microRNA processing , 2003, Nature.

[15]  G. Mack.  MicroRNA gets down to business , 2007, Nature Biotechnology.

[16]  Florian Caiment,et al.  A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep , 2006, Nature Genetics.

[17]  V. Álvarez,et al.  FGF20 rs12720208 SNP and microRNA-433 variation: No association with Parkinson's disease in Spanish patients , 2010, Neuroscience Letters.

[18]  M. Oshimura,et al.  Dicer is essential for formation of the heterochromatin structure in vertebrate cells , 2004, Nature Cell Biology.

[19]  A. Rego,et al.  Mechanisms of neurodegeneration in Huntington’s disease , 2008, European Journal of Neuroscience.

[20]  C. Croce,et al.  Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.

[21]  W. Schulz-Schaeffer,et al.  Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease , 2009, Molecular Neurodegeneration.

[22]  R. Russell,et al.  bantam Encodes a Developmentally Regulated microRNA that Controls Cell Proliferation and Regulates the Proapoptotic Gene hid in Drosophila , 2003, Cell.

[23]  Xun Hu,et al.  Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6 , 2009, Science.

[24]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[25]  Elena Cattaneo,et al.  A microRNA-based gene dysregulation pathway in Huntington's disease , 2008, Neurobiology of Disease.

[26]  Paul Pavlidis,et al.  Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model , 2008, Nature Genetics.

[27]  T. Sun,et al.  Different timings of dicer deletion affect neurogenesis and gliogenesis in the developing mouse central nervous system , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

[28]  S. Werner,et al.  The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair , 2005, Oncogene.

[29]  Frank Baas,et al.  UvA-DARE ( Digital Academic Repository ) In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid ( LNA ) antisense oligonucleotides , 2017 .

[30]  Margaret S. Ebert,et al.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.

[31]  D. Selkoe,et al.  Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. , 1987, Science.

[32]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[33]  J. Satoh,et al.  Aberrant microRNA expression in the brains of neurodegenerative diseases: miR‐29a decreased in Alzheimer disease brains targets neurone navigator 3 , 2010, Neuropathology and applied neurobiology.

[34]  Kwang-Soo Kim,et al.  Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. , 2003, Brain research. Molecular brain research.

[35]  Debomoy K Lahiri,et al.  MicroRNA-101 downregulates Alzheimer's amyloid-β precursor protein levels in human cell cultures and is differentially expressed. , 2011, Biochemical and biophysical research communications.

[36]  S. Melquist,et al.  Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.

[37]  S. Melquist,et al.  Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. , 2006, Human molecular genetics.

[38]  A. Abeliovich,et al.  Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Christina Thaller,et al.  miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis , 2008, Nature Neuroscience.

[40]  P. Wong,et al.  The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential , 2009, The Journal of Neuroscience.

[41]  Michael T. McManus,et al.  Conditional Loss of Dicer Disrupts Cellular and Tissue Morphogenesis in the Cortex and Hippocampus , 2008, The Journal of Neuroscience.

[42]  T. Woo,et al.  Neuronal type-specific gene expression profiling and laser-capture microdissection. , 2011, Methods in molecular biology.

[43]  S. Kauppinen,et al.  LNA-modified oligonucleotides mediate specific inhibition of microRNA function. , 2006, Gene.

[44]  Mauro Biffoni,et al.  The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.

[45]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[46]  C. Duijn,et al.  Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21 , 2006, Nature.

[47]  Xavier Estivill,et al.  MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. , 2011, Human molecular genetics.

[48]  J. Im,et al.  Repression of α-synuclein expression and toxicity by microRNA-7 , 2009, Proceedings of the National Academy of Sciences.

[49]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[50]  Elizabeth Head,et al.  Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human down syndrome brains. , 2013, The Journal of Biological Chemistry.

[51]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[52]  Peter T. Nelson,et al.  Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter , 2011, Acta Neuropathologica.

[53]  John McAnally,et al.  MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice , 2009, Science.

[54]  C. Tabin,et al.  miRNA malfunction causes spinal motor neuron disease , 2010, Proceedings of the National Academy of Sciences.

[55]  Xiaozhong Peng,et al.  MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice , 2012, Neurobiology of Aging.

[56]  S. Maas,et al.  Molecular diversity through RNA editing: a balancing act. , 2010, Trends in genetics : TIG.

[57]  Small RNAs: Delivering the future , 2007, Nature.

[58]  S. Booth,et al.  A miRNA Signature of Prion Induced Neurodegeneration , 2008, PloS one.

[59]  J. Yates,et al.  A role for the P-body component GW182 in microRNA function , 2005, Nature Cell Biology.

[60]  L. Buée,et al.  MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy , 2011, Alzheimer's & Dementia.

[61]  W. Lukiw,et al.  Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus , 2007, Neuroreport.

[62]  H. Iba,et al.  Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells , 2009, Nucleic acids research.

[63]  P. Provost,et al.  MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases , 2010, Brain Research.

[64]  V. Ambros,et al.  An Extensive Class of Small RNAs in Caenorhabditis elegans , 2001, Science.

[65]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[66]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[67]  Ted M. Dawson,et al.  Understanding microRNAs in neurodegeneration , 2009, Nature Reviews Neuroscience.

[68]  N. Sokol,et al.  Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression , 2010, Nature.

[69]  Qihong Huang,et al.  MicroRNAs can regulate human APP levels , 2008, Molecular Neurodegeneration.

[70]  Luc Buée,et al.  Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. , 2010, Human molecular genetics.

[71]  R. Shiekhattar,et al.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.

[72]  V. Ambros,et al.  MicroRNAs and Other Tiny Endogenous RNAs in C. elegans , 2003, Current Biology.

[73]  Yi Xing,et al.  The Bifunctional microRNA miR-9/miR-9* Regulates REST and CoREST and Is Downregulated in Huntington's Disease , 2008, The Journal of Neuroscience.

[74]  Phillip D Zamore,et al.  Sequence-Specific Inhibition of Small RNA Function , 2004, PLoS biology.

[75]  Hans Lassmann,et al.  The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution , 2005 .

[76]  B. Séraphin,et al.  Cytoplasmic foci are sites of mRNA decay in human cells , 2004, The Journal of cell biology.

[77]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[78]  Andrea Crotti,et al.  Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes , 2003, Nature Genetics.

[79]  Luigi Naldini,et al.  Stable knockdown of microRNA in vivo by lentiviral vectors , 2009, Nature Methods.

[80]  J. Trojanowski,et al.  FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α‐synuclein expression , 2009, Movement disorders : official journal of the Movement Disorder Society.

[81]  G. Nuovo,et al.  Chromosome 21-derived MicroRNAs Provide an Etiological Basis for Aberrant Protein Expression in Human Down Syndrome Brains* , 2009, The Journal of Biological Chemistry.

[82]  T. Tuschl,et al.  The Human DiGeorge Syndrome Critical Region Gene 8 and Its D. melanogaster Homolog Are Required for miRNA Biogenesis , 2004, Current Biology.

[83]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[84]  B. Chesebro.  Introduction to the transmissible spongiform encephalopathies or prion diseases. , 2003, British medical bulletin.

[85]  L. Bruijn,et al.  Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.

[86]  Juan Nunez-Iglesias,et al.  Joint Genome-Wide Profiling of miRNA and mRNA Expression in Alzheimer's Disease Cortex Reveals Altered miRNA Regulation , 2010, PloS one.

[87]  J L Haines,et al.  Supporting Online Material Materials and Methods Figs. S1 to S7 Tables S1 to S4 References Mutations in the Fus/tls Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis , 2022 .

[88]  P. Boyer,et al.  Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology , 2007, Proceedings of the National Academy of Sciences.

[89]  C. Croce,et al.  MicroRNA-133 controls cardiac hypertrophy , 2007, Nature Medicine.

[90]  G. Hutvagner,et al.  A microRNA in a Multiple-Turnover RNAi Enzyme Complex , 2002, Science.

[91]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[92]  Epaminondas Doxakis,et al.  Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153 , 2010, The Journal of Biological Chemistry.

[93]  Guiliang Tang,et al.  The Expression of MicroRNA miR-107 Decreases Early in Alzheimer's Disease and May Accelerate Disease Progression through Regulation of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 , 2008, The Journal of Neuroscience.

[94]  C. Barbato,et al.  MicroRNA-101 Regulates Amyloid Precursor Protein Expression in Hippocampal Neurons* , 2010, The Journal of Biological Chemistry.

[95]  Xun Hu,et al.  TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis , 2008, Science.

[96]  P. Nelson,et al.  MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. , 2010, Journal of Alzheimer's disease : JAD.

[97]  M. Farrer,et al.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.

[98]  G. Hannon,et al.  A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons , 2007, Science.

[99]  Praveen Sethupathy,et al.  MicroRNA target site polymorphisms and human disease. , 2008, Trends in genetics : TIG.

[100]  K. Sonntag,et al.  MicroRNAs and deregulated gene expression networks in neurodegeneration , 2010, Brain Research.

[101]  A. Ganser,et al.  Lentivirus-mediated antagomir expression for specific inhibition of miRNA function , 2007, Nucleic acids research.

[102]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[103]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[104]  E. Sontheimer,et al.  Distinct Roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA Silencing Pathways , 2004, Cell.

[105]  Robert E. Burke,et al.  Pitx3 is required for development of substantia nigra dopaminergic neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[106]  R. Petersen,et al.  Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia , 2008, Human molecular genetics.

[107]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[108]  Roy Parker,et al.  Decapping and Decay of Messenger RNA Occur in Cytoplasmic Processing Bodies , 2003 .

[109]  Nobuyuki Itoh,et al.  Preferential neurotrophic activity of fibroblast growth factor‐20 for dopaminergic neurons through fibroblast growth factor receptor‐1c , 2003, Journal of neuroscience research.

[110]  K. Sleegers,et al.  APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease , 2009, Human mutation.

[111]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[112]  A. Delacourte,et al.  Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expression , 2008, Proceedings of the National Academy of Sciences.

[113]  A. Akaike,et al.  FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. , 2000, Biochemical and biophysical research communications.

[114]  Olga Varlamova,et al.  A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.